These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 35454930)
21. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Lane AA; Garcia JS; Raulston EG; Garzon JL; Galinsky I; Baxter EW; Leonard R; DeAngelo DJ; Luskin MR; Reilly CR; Stahl M; Stone RM; Vedula RS; Wadleigh MM; Winer ES; Mughal T; Brooks C; Gupta IV; Stevenson KE; Neuberg DS; Ren S; Keating J; Konopleva M; Stein A; Pemmaraju N Blood Adv; 2024 Feb; 8(3):591-602. PubMed ID: 38052038 [TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis. Du Y; Li C; Yan J Hematology; 2023 Dec; 28(1):2198098. PubMed ID: 37036307 [TBL] [Abstract][Full Text] [Related]
23. Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience. Labrador J; Saiz-Rodríguez M; de Miguel D; de Laiglesia A; Rodríguez-Medina C; Vidriales MB; Pérez-Encinas M; Sánchez-Sánchez MJ; Cuello R; Roldán-Pérez A; Vives S; Benzo-Callejo G; Colorado M; García-Fortes M; Sayas MJ; Olivier C; Recio I; Conde-Royo D; Bienert-García Á; Vahi M; Muñoz-García C; Seri-Merino C; Tormo M; Vall-Llovera F; Foncillas MÁ; Martínez-Cuadrón D; Sanz MÁ; Montesinos P Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406512 [TBL] [Abstract][Full Text] [Related]
24. A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia. Bang SY; Park S; Kwag D; Lee JH; Min GJ; Park SS; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Kim HJ Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980551 [TBL] [Abstract][Full Text] [Related]
25. Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study. Weng G; Huang J; He X; Xue T; Yang L; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Jin H; Liu Q; Du X Ann Hematol; 2023 Dec; 102(12):3369-3381. PubMed ID: 37723307 [TBL] [Abstract][Full Text] [Related]
26. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia. Weng G; Zhang Y; Yu G; Luo T; Yu S; Xu N; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Shao R; Du X; Jin H; Liu Q J Intern Med; 2023 Mar; 293(3):329-339. PubMed ID: 36284445 [TBL] [Abstract][Full Text] [Related]
28. HMA/VEN treatment modifications and associated outcomes in Chin KK; Derkach A; Famulare C; Gupta GK; Borge PD; Geyer MB; Goldberg AD; Haque T; Park JH; Roeker LE; Tallman MS; Stahl M; Stein EM Leuk Lymphoma; 2024 Oct; ():1-9. PubMed ID: 39397429 [TBL] [Abstract][Full Text] [Related]
29. Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms. Carter JL; Su Y; Qiao X; Zhao J; Wang G; Howard M; Edwards H; Bao X; Li J; Hüttemann M; Yang J; Taub JW; Ge Y Biochem Pharmacol; 2023 Oct; 216():115759. PubMed ID: 37604291 [TBL] [Abstract][Full Text] [Related]
31. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397 [TBL] [Abstract][Full Text] [Related]
32. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. Zeidan AM; Pollyea DA; Borate U; Vasconcelos A; Potluri R; Rotter D; Kiendrebeogo Z; Gaugler L; Prebet T; Strocchia M; Bonifacio G; Chen C Ann Hematol; 2023 Apr; 102(4):749-754. PubMed ID: 36732419 [TBL] [Abstract][Full Text] [Related]
33. Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia. Cui J; Chen X; Li C; Yan Q; Yuan G Hematology; 2024 Dec; 29(1):2293512. PubMed ID: 38095287 [TBL] [Abstract][Full Text] [Related]
34. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Wang YW; Tsai CH; Lin CC; Tien FM; Chen YW; Lin HY; Yao M; Lin YC; Lin CT; Cheng CL; Tang JL; Chou WC; Hou HA; Tien HF Ann Hematol; 2020 Mar; 99(3):501-511. PubMed ID: 31965269 [TBL] [Abstract][Full Text] [Related]
35. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis. Liu B; Guo Y; Deng L; Qiao Y; Jian J Hematology; 2020 Dec; 25(1):414-423. PubMed ID: 33191860 [TBL] [Abstract][Full Text] [Related]
36. Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study. Mustafa Ali MK; Corley EM; Alharthy H; Kline KAF; Law JY; Lee ST; Niyongere S; Duong VH; Emadi A; Baer MR Front Oncol; 2022; 12():858202. PubMed ID: 35433414 [TBL] [Abstract][Full Text] [Related]
37. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301 [TBL] [Abstract][Full Text] [Related]
38. Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis. Guinan K; Mathurin K; Au Y; Schuh AC; Bui CN; Chai X; Lachaine J Curr Oncol; 2022 Oct; 29(10):7524-7536. PubMed ID: 36290869 [TBL] [Abstract][Full Text] [Related]
39. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Pollyea DA; Pratz K; Letai A; Jonas BA; Wei AH; Pullarkat V; Konopleva M; Thirman MJ; Arellano M; Becker PS; Chyla B; Hong WJ; Jiang Q; Potluri J; DiNardo CD Am J Hematol; 2021 Feb; 96(2):208-217. PubMed ID: 33119898 [TBL] [Abstract][Full Text] [Related]
40. Venetoclax-based salvage therapy as bridge-to-transplant is feasible and effective in patients with relapsed/refractory AML. Unglaub JM; Schlenk RF; Middeke JM; Krause SW; Kraus S; Einsele H; Kramer M; Zukunft S; Kauer J; Renders S; Katelari E; Schliemann C; Pabst C; Luft T; Dreger P; Röllig C; Bornhäuser M; Müller-Tidow C; Sauer T Blood Adv; 2024 Sep; ():. PubMed ID: 39293081 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]